 Document Type:   Protocol and Protocol Amendments 
Official Title:    A multicenter, 52 to 104 week extension study to 
    evaluate the long term growth and development of 
    pediatric hypertensive patients 6 –17 years of age treated  
    previously with aliskiren  
Study ID: [REMOVED] 
Document Release Date:  Final Protocol:  10 June 2011 
 
 
 
Clinical Development 
SPP100A/Aliskiren 
Clinical Trial Protocol CSPP100A2365E2 
A multicenter, 52 to 104 week extension study to evaluate 
the long term growth and development of pediatric 
hypertensive patients 6 – 17 years of age treated previously 
with aliskiren 
Authors: Satlin Li InYoung 
Document type: Clinical Trial Protocol 
Version number: Original protocol Development phase: III  Release date: 10-Jun-2011 
Property of Novartis 
Confidential 
May not be used, divulged, published, or otherwise disclosed 
Template version 24 May 2011 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 2 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
Table of contents 
Table of contents ............................................................................................................. .... 2 
List of tables ........................................................................................................................ 4 
List of figures ...................................................................................................................... 4 
Protocol synopsis ................................................................................................................. 7 
1 Introduction .................................................................................................................. ....... 9 
1.1 Background .............................................................................................................. 9 
1.2 Purpose .................................................................................................................. 11 
2 Study objectives ................................................................................................................. 11 
2.1 Primary objectives ................................................................................................. 11 
2.2 Secondary objectives ............................................................................................. 12 
2.3 Exploratory objectives ........................................................................................... 12 
3 Investigational plan ........................................................................................................... 12 
3.1 Study design........................................................................................................... 12 
3.2 Rationale of study design ....................................................................................... 12 
3.3 Rationale of dose/regimen, duration of treatment ................................................. 13 
3.4 Rationale for choice of comparator ....................................................................... 13 
3.5 Purpose and timing of interim analyses/design adaptations .................................. 13 
4 Population .................................................................................................................... ...... 13 
4.1 Inclusion criteria .................................................................................................... 13 
4.2 Exclusion criteria ................................................................................................... 13 
5 Treatment ..................................................................................................................... ...... 14 
5.1 Investigational and control treatment .................................................................... 14 
5.2 Treatment arms ...................................................................................................... 14 
5.3 Treatment assignment ............................................................................................ 14 
5.4 Treatment blinding ................................................................................................. 14 
5.5 Treating the patient ................................................................................................ 14 
5.5.1  Patient numbering ................................................................................. 14 
5.5.2  Dispensing the study treatment ............................................................. 14 
5.5.3  Supply, storage and tracking of study treatment ................................... 14 
5.5.4  Instructions for prescribing and taking study treatment ........................ 14 
5.5.5  Permitted dose adjustments and inte rruptions of study treatment ........ 14 
5.5.6  Rescue medication ................................................................................ 14 
5.5.7  Concomitant treatment .......................................................................... 14 
5.5.8  Prohibited treatment .............................................................................. 15 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 3 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
5.5.9  Discontinuation of study treat ment and premature patient 
withdrawal ............................................................................................. 15 
5.5.10 Emergency unblinding of treatment assignment ................................... 15 
5.5.11 Study completion and post-study treatment .......................................... 15 
5.5.12 Early study termination ......................................................................... 15 
6 Visit schedule and assessments ......................................................................................... 16 
6.1 Information to be collected on screening failures.................................................. 16 
6.2 Patient demographics/other  baseline characteristics ............................................. 16 
6.3 Treatment exposure and compliance ..................................................................... 16 
6.4 Efficacy .................................................................................................................. 16 
6.5 Safety ..................................................................................................................... 16 
6.5.1  Height and weight ................................................................................. 16 
6.5.2  Laboratory evaluations .......................................................................... 16 
6.5.3  Clinical chemistry ................................................................................. 17 
6.5.4  Pregnancy and assessm ents of fertility ................................................. 17 
6.5.5  Appropriateness of safe ty measurements .............................................. 17 
6.6 Other assessments .................................................................................................. 17 
6.6.1  Neurocognitive evaluation .................................................................... 17 
6.6.2  Resource utilization ............................................................................... 17 
6.6.3  Health-related Quality of Life ............................................................... 17 
6.6.4  Pharmacokinetics .................................................................................. 18 
6.6.5  Pharmacogenetics/pharmacogenomics ................................................. 18 
6.6.6  Other biomarkers ................................................................................... 18 
7 Safety monitoring .............................................................................................................. 18 
7.1 Adverse events ....................................................................................................... 18 
7.2 Serious adverse event reporting ............................................................................. 18 
7.3 Pregnancies ............................................................................................................ 19 
8 Data review and data base management ............................................................................. 19 
8.1 Site monitoring ...................................................................................................... 19 
8.2 Data collection ....................................................................................................... 20 
8.3 Database management and quality control ............................................................ 20 
9 Data analysis ................................................................................................................. ..... 20 
9.1 Analysis sets .......................................................................................................... 21 
9.2 Patient demographics and ot her baseline characteristics ....................................... 21 
9.3 Treatments ............................................................................................................. 21 
9.4 Analysis of the primary variable(s) ....................................................................... 21 
9.4.1  Variable ................................................................................................. 21 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 4 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
9.4.2  Statistical model, hypothesis,  and method of analysis .......................... 21 
9.4.3  Handling of missing values/censoring/discontinuations ....................... 21 
9.4.4  Supportive analyses ............................................................................... 21 
9.5 Analysis of secondary variables ............................................................................ 22 
9.5.1  Key secondary variables ....................................................................... 22 
9.5.2  Efficacy variables .................................................................................. 22 
9.5.3  Safety variables ..................................................................................... 22 
9.5.4  Pharmacokinetics .................................................................................. 22 
9.5.5  Pharmacogenetics/pharmacogenomics ................................................. 22 
9.5.6  Biomarkers ............................................................................................ 22 
9.5.7  PK/PD ................................................................................................... 22 
9.6 Sample size calculation .......................................................................................... 22 
9.7 Power for analysis of ke y secondary variables ...................................................... 22 
9.8 Interim analyses ..................................................................................................... 23 
10 Ethical considerations ........................................................................................................ 23 
10.1 Regulatory and ethical compliance ........................................................................ 23 
10.2 Informed consent procedures ................................................................................. 23 
10.3 Responsibilities of the inve stigator and IRB/IEC .................................................. 23 
10.4 Publication of study protocol and results............................................................... 24 
11 Protocol adherence ............................................................................................................  24 
11.1 Protocol Amendments ........................................................................................... 24 
12 References .................................................................................................................... ..... 25 
13 Appendix 1: Clinically notable laboratory values ............................................................. 26 
14 Appendix 2:  Neurocog nitive assessment .......................................................................... 27 
 
List of tables 
Table 3-1   Study design .......................................................................................... 12 
Table 6-1   Assessment schedule ............................................................................. 16 
Table 13-1   Clinically notable laboratory values...................................................... 26 
Table 14-1   Neurocognitive tests .............................................................................. 27 
 
List of figures 
Figure 3-1   Study design .......................................................................................... 12 
 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 5 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
List of abbreviations 
AE  adverse event 
ALT  alanine aminotransferase AST  aspartate aminotransferase eCRF  Electronic Case Report Form CPO  Country Pharma Organization CRO  Contract Research Organization 
DS&E  Drug Safety & Epidemiology 
ECG  Electrocardiogram EDC  Electronic Data Capture EFS  Enrolled to follow-up set ICH International Conference on Harmonization of Technical Requirements for    
Registration of Pharmaceuticals for Human Use 
IEC   Independent Ethics Committee IRB  Institutional Review Board IVRS  Interactive Voice Response System  PIP   Pediatric Investigational Plan 
SAE  serious adverse event 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 6 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
Glossary of terms 
Assessment A procedure used to generate data required by the study 
Control drug A study drug used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug 
Enrollment Point/time of patient entry into the study; the point at which informed consent must be obtained (i.e. prior to starting any of the procedures described in the protocol) 
Investigational drug The study drug whose properties are being tested in the study; this definition is consistent with US CFR 21 Section 312.3 and is synonymous with “investigational new drug.” 
Medication number A unique identifier on the label of each study drug package in studies that dispense study drug using an IVR system 
Patient number A number assigned to each patient who enrolls in the study. When combined with the center number, a unique identifier is created for each 
patient in the study. 
Period A minor subdivision of the study timeline; divides phases into smaller 
functional segments such as screening, baseline, titration, washout, etc. 
Premature patient withdrawal Point/time when the patient exits from the study prior to the planned 
completion of all study drug administration and assessments; at this time 
all study drug administration is discontinued and no further assessments 
are planned 
Randomization number A unique identifier assigned to each randomized patient, corresponding to 
a specific treatment arm assignment 
Stage A major subdivision of the study timeline; begins and ends with major study milestones such as enrollment, randomization, completion of treatment, etc. 
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study drug was discontinued whichever is later 
Study drug Any drug administered to the patient as part of the required study procedures; includes investigational drug and any control drugs 
Study drug discontinuation Point/time when patient permanently stops taking study drug for any reason; may or may not also be the point/time of premature patient 
withdrawal 
Variable Information used in the data analysis; derived directly or indirectly from data collected using specified assessments at specified timepoints 
 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 7 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
Protocol synopsis 
Title of study :  A multicenter, 52 to 104 week off-therapy extension study to evaluate the long term 
growth and development of pediatric hypertensive patients 6 – 17 years of age previously treated with 
aliskiren in studies CSPP100A2365 and/or CSPP100A2365E1  
Purpose and rationale :  The purpose of this 52 to 104 week off-therapy follow-up to studies 
CSPP100A2365 and CSPP100A2365E1 is to evaluate the long term growth and development of 
children 6 – 17 years old (6 to less than 18 years old at baseline in study CSPP100A2365) with hypertension (msSBP ≥  95
th percentile for age, gender and height) at baseline in study 
CSPP100A2365, previously treated with aliskiren.  Patients identified in study CSPP100A2365 to have primary hypertension will be followed for 52 weeks (1 year) after the completion of study CSPP100A2365E1.  Patients identified in study CSPP100A2365 to have secondary hypertension will be followed for 104 weeks (2 years) after the completion of study CSPP100A2365E1.  The assessment of growth and development through height and weight measurement will be performed on all patients for 52 weeks, after which patients with primary hypertension will complete.  The 
assessment of patients with secondary hypertension will continue for an additional 52 weeks during 
which growth and development will continue to be assessed with added neurocognitive and renal function evaluations. 
This study is in compliance with the EMA PIP Positive Opinion in support of the monotherapy 
registration of aliskiren for the treatment of hypertension in pediatric patients 6 – 17 years of age. 
Objectives:  
• To evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years 
of age when previously treated with aliskiren 
Population: The study population will consist of male and female hypertensive pediatric patients who 
have completed the CSPP100A2365E1 protocol.  These patients were 6 – 17 years old and had an 
msSBP ≥ 95
th percentile for age, gender and height at baseline (randomization) in study 
CSPP100A2365.  Patients will continue to be stratified by CSPP100A2365 baseline weight, age, 
hypertension etiology and region.  Centers from the US and EU participating in CSPP100A2365 and CSPP100A2365E1 will participate in this off-therapy follow-up.  
Inclusion/Exclusion criteria:  All patients are to have met entry inclusion and exclusion criteria for CSPP100A2365 and 
CSPP100A2365E1. 
• Successful completion of the CSPP100A2365E1 protocol 
• Written informed consent; patients who are eligible to participate in this long-term off-therapy 
extension and whose parent(s)/guardian (s) consent in writing to their doing so after the purpose 
and nature of this investigation has been clearly explained to them.  An assent will be obtained for 
some patients depending upon their age, maturity, capacity for understanding, and the local 
requirements regarding assents.  Written informed consent must be obtained before any 
assessment is performed.  
Investigational and reference therapy:  
• Investigational therapy:  none 
• Reference therapy:  none 
Study medication is not used in this trial. 
Study design: This is a multicenter, 52 to 104 week off-therapy extension to evaluate long-term 
growth and development in pediatric hypertensive patients 6 – 17 years of age at initiation of treatment 
with aliskiren in study CSPP100A2365.  Eligible patients will continue to be stratified by age (6 to 11 
years and 12 to 17 years) at study CSPP100A2365 baseline (Visit 2) and by etiology of hypertension 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 8 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
(primary and secondary).  Likewise, stratifications by weight group and region assigned at study CSPP100A2365 will remain. 
Efficacy assessments:  Not applicable.  Safety assessments:  
• At LT weeks 104 and 156 height and weight measurements 
• At LT weeks 104 and 156 renal function evaluation only in patients with secondary hypertension  
Other assessments:  
• At LT weeks 104 and 156 neurocognitive evaluation only in patients with secondary hypertension  
Data analysis :  Demographics and baseline characteristics, safety data (height, weight, derived BMI, 
laboratory evaluations, SAE) and other data as appropriate, will be summarized descriptively by 
treatment regimen from CSPP100A2365E1. 
For the superiority assessment of change in weight, the null hypothesis to be tested is that the mean 
change of weight in the aliskiren regimen is equal to that in the enalapril regimen, versus the alternative hypothesis that they are not equal: 
H
0: µ1 = µ 2 versus H 1: µ1 ≠ µ2 
The statistical test for change from baseline in weight will be performed using an analysis of 
covariance (ANCOVA) model with treatment regimen from CSPP10AE1, region (US, EU), age strata (6 to 11 years, 12 to 17 years), and hypertension etiology (primary, secondary) as factors, and with baseline weight as covariate.  The statistical test will be made at two-sided significance level of 0.05. The 95% confidence interval will be provided.  
Changes from baseline in height and derived BMI will be analyzed using the similar model. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 9 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
1 Introduction 
1.1 Background 
The renin-angiotensin system (R AS) plays a major role in the regulation of arterial blood 
pressure and the pathogenesis of hypertension.  Renin is secreted by the kidney in response to 
a decrease in circulating volume and blood pressure.  It cleaves the substrate angiotensinogen 
to form the inactive decapeptide angiotensin I (Ang I).  Angiotensin I is converted to the 
active octapeptide angiotensin II by angiotensi n converting enzyme (ACE).  Angiotensin II 
interacts with cellular receptors (angiotensin II receptors) and through different mechanisms increases total peripheral resistance, resu lting in the elevation of blood pressure. 
Blocking RAS with an ACE inhibitor or angi otensin II receptor blocker (ARB) has been 
commonly used in clinical practice for the treatment of patients with hypertension.  An alternative approach to blockade of the RAS is inhibition of renin, the rate limiting enzyme for the formation of angiotensin II.  Until recen tly, the introduction of renin inhibitors into 
clinical practice was limited by low oral bio-availability, short duration of action and high cost of chemical synthesis.  Aliskiren (SPP 100) is the first new, orally active, non-peptide, specific direct renin inhibitor and has been ap proved for use in adults in the treatment of 
hypertension. 
Aliskiren is a non-peptide with a low molecular we ight (609.8).  In vitro, it is a potent direct 
inhibitor of human renin (IC50 = 0.6 nM).  In vi vo, aliskiren administered both orally (p.o.) or 
intravenously (i.v.) in several studies with  sodium-depleted marmosets caused complete 
inhibition of plasma renin activity (PRA), sust ained reductions in mean arterial pressure 
(MAP), and significant increases in plasma concentrations of active and total renin.  In 
humans, plasma concentrations of aliskiren increase rapidly after administration reaching peak levels usually within 1-3 hours.  The hal f-life of aliskiren is approximately 40 hours and 
its bioavailability is approximately 2.6%.  Renal and hepatic clearance of aliskiren is minimal.  Changes in renal and hepatic function related to age are not anticipated to alter aliskiren elimination within the proposed range of 6 to  17 years.  Aliskiren is excreted mostly 
unchanged by the fecal route (~90%).  About 0.6% of an oral dose is renally excreted. 
In the adult population, aliskiren has been studi ed in clinical trials involving over 12,000 
patients with hypertension.  It has been demons trated to be efficacious and safe when used 
alone or in combination with other antihypertensives for the treatment of hypertension.  In a 
clinical study in patients with mild to modera te hypertension, 652 patie nts were randomized to 
receive placebo, aliskiren 150, 300 or 600 mg or 150 mg of irbesartan once daily for 8 weeks.  Patients receiving aliskiren 150 mg and 300 mg demonstrated dose related decreases in both 
systolic and diastolic blood pressu re.  No additional blood pressure  lowering effects were seen 
with aliskiren 600 mg as compared with aliski ren 300 mg.  Aliskiren 150 mg was comparable 
to irbesartan 150 mg in reduc ing diastolic blood pressure (D BP) while aliskiren 300 mg and 
600 mg showed a significantly greater DBP redu ction than irbesartan 150 mg.  The overall 
incidences of adverse events seen in patient s receiving aliskiren (150 mg and 300 mg) were 
similar to placebo.  There was a slight increase in GI adverse events (especially diarrhea) at the 600mg aliskiren dose. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 10 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
In a 26-week, randomized, double-blind st udy with 1124 randomized patients, the 
combination of aliskiren with amlodipine was demonstrated to be effective and well tolerated.  
In addition, the efficacy and safety of the comb ination of aliskiren with  HCTZ were shown in 
a 26-week, double-blind, randomized active-cont rolled study with a total number of 842 
patients with hypertension. 
The effect of aliskiren on the development of the juvenile rat was explored in three toxicology 
studies.  The effects of aliskiren have been tested  in rats treated by gavage at 50, 150 or 300 
mg/kg/day from days 14 to 34 post-partum.  Ef fects on mortality, clinical signs, and body 
weight were measured, and following euthanasia  at day 34, gross and microscopic pathology 
were examined.  No deaths were noted.  Diarrhea was present in most animals at the higher 
doses.  Dose-related 15-50% reductions in body weight gain as compared to controls were 
found early in the course of treatment, but tended to  be slightly higher than controls thereafter.  
In other studies in which rats were treated by gavage with aliskiren at 30, 100, or 300 
mg/kg/day from post-partum day 8 to 35 and 14 to 70, respectively, morbidity (12-57% weight loss, diarrhea, and 20-30% reduction in the absolute lymphocyte count) and mortality 
(1 death at 100 mg/kg/day and 4 deaths at 300 mg/kg/day) were observed as in the 34 day 
study.  Pharmacokinetic measurements in these studies showed that aliskiren exposure (AUC 
in ng-h/ml) was 19-36% greater in 8 day old than in 14 day old rats at the 30 mg/kg/day dose, but more than 350% (3.5 fold) greater at the 100 mg/kg/day dose.  Remarkably, the AUC was more than 350-fold greater in 14 day old than the 64 day old rats at the 30 mg/kg/day dose, 150-fold greater at the 100 mg/kg/day dose, and 85-fold greater in 14 day old than the 64 day old rats at the 300 mg/kg/day dose.  Moreover, the variability in exposure was more than twice as great when the animals were younger than when they were older. 
These findings demonstrate that  aliskiren exposure is age related with declining exposure 
possibly related to the maturation of transporters and/or metabolizing systems.    In humans, drugs that act directly on the renin-angiotensin system can cause injury and even 
death to the developing fetus when administer ed to pregnant women.  When pregnancy is 
detected, aliskiren should be di scontinued as soon as possible.  For complete details of the 
toxicology program for aliskiren please refer to  the SPP100 Aliskiren Investigator’s Brochure. 
As the first direct renin inhibitor for the treat ment of hypertension in adults, aliskiren is 
proposed for use in hypertensive children 6-17 y ears of age, as an alternative to currently 
available therapies.  Aliskiren may offer a therapeutic profile distinct from that of ACE 
inhibitors and ARBs ( Frampton and Curran 2007 ).  The course of hypertension and the effects 
of antihypertensive medications in adolescents are not likely to differ from the course of the disease and the effects of antihypertensive medications in adults.  The pediatric study for which this is an off-therapy follow-up will in clude a reasonable proportion of school-age, pre-
pubertal children with at least 50% of the children being 6-11 years of age. 
As the prevalence of hypertension in children increases ( Soroff, et al 2004 ) treatment 
alternatives to those currently available will be  of increasing significance.  It is known that 
hypertension prevalence increases progressively with increased BMI and in the pediatric population hypertension is detectable in ap proximately 30% of overweight children ( NHLBI 
12
th Report, 2004).  Obesity is thought to be a major contributor to essential hypertension in 
school age children and adolescents ( Weinberger, et al 2008 ).  Primary essential hypertension 
in children is generally mild and associated with a positive family history of hypertension or 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 11 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
CVD and mild/moderate/severe obesity.  Aliskire n may therefore be particularly important in 
children 6-17 years of age with essential hype rtension since it has been shown to be of 
comparable efficacy in obese adult patients compared to those of normal body mass index 
(BMI) ( Jensen, et al 2008 ). 
In summary, the efficacy and tolerability of aliskiren alone or in combination with other 
agents are comparable to other commonly used antihypertensive medications in adults.  Given 
the results reported with aliskiren in adults with hypertension, a similar efficacy and 
tolerability of aliskiren in children 6-17 years of age would be anticipated, providing an additional treatment option for children with hypertension. 
This study is intended to evaluate the off-th erapy long term growth and development of 
children 6 – 17 years old after exposure to a liskiren for at least one year in studies 
CSPP100A2365 and CSPP100A2365E1, and was developed to comply with the EMA 
Pediatric Committee Pediatric Investigational Plan (PIP). 
In study CSPP100A2365 the dose-response, efficacy and safety of aliskiren was evaluated in 
double-blind fashion over 8 weeks.  Study CSPP100A2365E1 provided double blind 
evaluation of the long-term safety, tolerability and efficacy of aliskiren compared to enalapril 
in the same patient population. 
1.2 Purpose  
The purpose of this 52 to 104 week off-therapy extension to studies CSPP100A2365 and 
CSPP100A2365E1 is to evaluate the long term growth and developmen t of children 6 – 17 
years old (6 to less than 18 years old at ba seline in study CSPP100A2365) with hypertension 
(msSBP ≥ 95th percentile for age, gender and height) at baseline in study CSPP100A2365, 
previously treated with aliskiren.  Patients identified in study CSPP100A2365 to have primary 
hypertension will be followed for 52 weeks (1 year) after the completion of study CSPP100A2365E1.  Patients identified in study CSPP100A2365 to have secondary hypertension will be followed for 104 weeks (2  years) after the completion of study 
CSPP100A2365E1.  The assessment of growth a nd development through height and weight 
measurement will be performed on all patients for 52 weeks after which patients with primary hypertension will complete.  The assessment of  patients with secondary hypertension will 
continue for an additional 52 weeks during which growth and development will continue to be assessed with added neurocognitive and renal function evaluations as follow-up measures. 
This study is in compliance with the EMA PIP Positive Opinion in support of the monotherapy registration of aliskiren for the treatment of hypertension in pediatric patients 6 
– 17 years of age. 
2 Study objectives 
2.1 Primary objectives 
• To evaluate the long term growth and devel opment of pediatric hypertensive patients aged 
6 – 17 years when treated previously with aliskiren 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 12 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
2.2 Secondary objectives 
Not applicable. 
2.3 Exploratory objectives 
Not applicable. 
3 Investigational plan 
3.1 Study design 
This is a multicenter 52 to 104 week off-therapy extension to evaluate long-term growth and 
development in pediatric hypertensive patients 6 – 17 years of age at initiation of treatment 
with aliskiren in study CSPP100A2365.  Eligible patient s will continue to be  stratified by age 
(6 – 11 years and 12 – 17 years) at study CSPP 100A2365 baseline (Visit 2) and by etiology of 
hypertension (primary and secondary).  Likewi se, stratifications by weight group and region 
assigned in study CSPP100A2365 will remain. 
Table 3-1 Study design 
CSPP100A2365E2 LT Safety Follow-up  
Week 52 LT (end of study visit 
CSPP100A2365E1) Week 104 LT Week 156 LT 
Day 365 (LT) Day 730 (LT) Day1095 (LT) 
Visit 17* Visit 18** Visit 19*** 
* Long-term (LT) safety extension visit numbers continue from CSPP100A2365E1 
** End of study for patients with primary hypertension *** End of study for patients with secondary hypertension 
Figure 3-1 Study design 
    
  
  Primary 
hypertension
  
          
  Secondary 
hypertension
      
      
                            Visit 17, LT Wk 52               Vi si t 18, LT Wk 104             Visit 19, LT Wk 156 
 
3.2 Rationale of study design 
This study is being conducted to comply with the EMA PIP Positive Opinion for the provision 
of long-term growth and development data including renal function and neurocognitive function data in children w ith secondary hypertension. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 13 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
3.3 Rationale of dose/regimen, duration of treatment 
Not applicable. 
3.4 Rationale for choice of comparator 
Not applicable. 
3.5 Purpose and timing of interim analyses/design adaptations 
Not applicable.  
4 Population 
The study population will consist of male and female hypertensive pediatric patients who 
have completed the CSPP100A2365E 1 protocol.  These patients were 6 – 17 years old and 
had an msSBP ≥ 95th percentile for age, gender and heig ht at baseline (randomization) in 
study CSPP100A2365.  Patients will continue to be stratified by CSPP100A2365 baseline 
weight, age, hypertension etiology and region.  Centers from the US and EU participating in CSPP100A2365 and CSPP100A2365E1 w ill participate in this off-therapy follow-up. 
4.1 Inclusion criteria 
Patients eligible for inclusion in this study have to fulfill all of the following criteria: 
1. Informed consent form (approved by the Institutional Review Board (IRB)/Independent 
Ethics Committee (IEC), signed by the parent(s)/legal guardian(s), after the purpose and nature of the investigation has been clearly explained to the parents and the patient.  An 
assent will be obtained for some patients depending upon their age, maturity, capacity for understanding, and the local requirements rega rding assents.  Written informed consent 
must be obtained before an y assessment is performed. 
2. Male or female pa tients ages 6 – 17 years at Visit 2 (randomization) in study 
CSPP100A2365, with a documented diagnosis of hypertension as defined in the NHLBI 
12
th Report 2004  
3. msSBP (mean of 3 systolic blood pressure measurements) ≥ 95th percentile for age, gender 
and height at Visit 2 (random ization) in study CSPP100A2365 
4. ≥ 20 kg and ≤ 150 kg at Visit 2 (randomization) in study CSPP100A2365 
5. Successful completion of study  CSPP100A2365E1 
4.2 Exclusion criteria 
1. Patients who did not successfully comp lete study CSPP100A2365 and CSPP100A2365E1 
are excluded from participation in CSPP100A2365E2. 
2. No additional exclusions may be applied by the investigator, in order to ensure that the 
study population will be representa tive of all elig ible patients. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 14 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
5 Treatment 
5.1 Investigational and control treatment 
Not applicable. 
5.2 Treatment arms 
Not applicable. 
5.3 Treatment assignment 
Not applicable. 
5.4 Treatment blinding 
Not applicable. 
5.5 Treating the patient 
5.5.1 Patient numbering 
Each patient is uniquely identified in the stud y by a combination of his/her center number and 
patient number.  The center number was assigned by Novartis to the investigative site in trial 
CSPP100A2365.  Upon signing the informed consent form and assent form, if applicable, the 
patient will continue to use the patient number assigned by the investigator in trial CSPP100A2365.  Only the assigned patient numb er should be entered in the field labeled 
“Patient ID” on the EDC data entry screen (e.g. enter ‘1’, ‘2’, etc.). 
5.5.2 Dispensing the study treatment 
Not applicable. 
5.5.3 Supply, storage and tracking of study treatment 
Not applicable. 5.5.4 Instructions for prescribing and taking study treatment 
Not applicable. 
5.5.5 Permitted dose adjustments and interruptions of study treatment 
Not applicable. 5.5.6 Rescue medication 
Not applicable. 
5.5.7 Concomitant treatment 
The investigator should instruct the patient to notify the study site about any new medications 
he/she takes after the start of the study.  A ll medications and signif icant non-drug therapies 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 15 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
(including physical therapy and blood transf usions) administered must be listed on the 
Concomitant medications/Signifi cant non-drug therapies eCRF. 
5.5.8 Prohibited treatment 
Not applicable. 
5.5.9 Discontinuation of study treatment  and premature patient withdrawal 
Patients may voluntarily withdraw from the study for any reason at any time. They may be 
considered withdrawn if they state an intention to withdraw, fail to return for visits, or become lost to follow-up for any other reason. 
If premature withdrawal occurs for any reason, the investigator must make every effort to 
determine the primary reason for a patient’s premature withdrawal from the study and record 
this information on the Study Completion eCRF. 
For patients who are lost to follow-up (i.e. those patients whose status is unclear because they 
fail to appear for study visits without stating an  intention to withdraw), the investigator should 
show "due diligence" by documenting in the source documents steps taken to contact the 
patient, e.g. dates of telephone ca lls, registered letters, etc. 
Patients who are prematurely withdrawn from th e study will not be replaced by an equal 
number of newly enrolled patients. 
5.5.10 Emergency unblinding of treatment assignment 
Not applicable. 
5.5.11 Study completion and post-study treatment 
Patients identified in study CSPP100A2365 as ha ving primary hypertension should complete 
Visit 18 with assessments.  Patients identified in study C SPP100A2365 as having secondary 
hypertension should complete Visit 19 with assessments.  The study will end when all 
enrolled patients have completed last visit, last assessment. 
5.5.12 Early study termination 
The study can be terminated at any time for any reason by Novartis.  Should this be necessary, 
the patient should be seen as soon as possible and treated as described in Section 6 for a 
prematurely withdrawn patient.  The investigator may be informed of additional procedures to 
be followed in order to ensure that adequate consideration is given to  the protection of the 
patient’s interests.  The investigator will be responsible for informing IRBs and/or ECs of the early termination of the trial. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 16 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
6 Visit schedule and assessments 
Table 6-1 Assessment schedule 
Visit C4 LT171 LT18 LT193 
Week  52 104 156 
Informed consent/child assent S X   
Height D X X X 
Weight D X X X 
Concomitant Medication D X X X 
Neurocognitive Evaluation D  X3 X 
Chemistry D  X3 X 
Study Completion Form D  X2 X 
1 Extension 2 – Visit LT (long term) 17 should occur on the same day as CSPP100A2365E1 “end of 
study” V16.    Data for other identified evaluations will be obtained from Study CSPP100A2365E1. 
2 Visit LT18 is the end of study visit for patients identified in the core study (CSPP100A2365) as having 
primary hypertension. 
3 For patients with secondary hypertension only.  
4 C is the category; D = eCRF data, S = source document data 
6.1 Information to be collected on screening failures 
Not applicable. 
6.2 Patient demographics/other baseline characteristics 
Patient demographic data and baseline characteristic data will have been collected in study 
CSPP100A2365.  The stratifications applied in  the core study will remain in place.  
6.3 Treatment exposure and compliance 
Not applicable. 
6.4 Efficacy 
Not applicable. 
6.5 Safety 
6.5.1 Height and weight 
Height in centimeters (cm) and body weight (t o the nearest 0.1 kilogram [kg] in indoor 
clothing, but without shoes) will be measur ed at all visits.  BMI will be derived. 
6.5.2 Laboratory evaluations A central laboratory will be used for analysis of all specimens collected. Details on the 
collections, shipment of samp les and reporting of results by  the central laboratory are 
provided to investigators in the laboratory manual. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 17 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
Clinically notable laborator y findings are defined in Appendix 1 . 
6.5.3 Clinical chemistry 
Serum creatinine, blood urea, sodium, potassium, chloride and calcium will be measured at 
LT Visits 18 and 19 (patients with secondary hypertension only). 
6.5.4 Pregnancy and assessments of fertility 
Not applicable. 
6.5.5 Appropriateness of safety measurements 
The safety assessments selected are standa rd for this indication/patient population.  
6.6 Other assessments 
6.6.1 Neurocognitive evaluation All patients who were determined to have secondary hypertension in study CSPP100A2365 
and have a baseline (Visit 2) neurocognitive assessment w ill receive a neurocognitive 
assessment at LT V18 and LT V19. 
The neurocognitive assessment of development will include assessment of the following 
abilities: 
• Attention 
• Processing speed 
• Working memory 
• Motor speed 
These assessments were chosen based on their validity and reliability, ease and efficiency of 
administration and scoring by non-psychologists, availability, appropriateness for the age span included in this study and ability to be repeated without significant practi ce effect (defined as 
improvement in performance based solely on prev ious exposure to or practice with the test).  
A manual for standardized administration of the neurocognitive evaluation and scoring procedures for all assessments will be provided separately to each site.  The same battery of 
tests administered in the same order, wh ere possible, will be used for each patient. 
Appendix 2  further outlines the neurocognitive assessment of development as it applies to this 
protocol and study population. 
6.6.2 Resource utilization 
Not applicable. 
6.6.3 Health-related Quality of Life 
Not applicable. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 18 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
6.6.4 Pharmacokinetics 
Not applicable. 
6.6.5 Pharmacogenetics/pharmacogenomics 
Not applicable. 
6.6.6 Other biomarkers 
Not applicable. 
7 Safety monitoring 
7.1 Adverse events 
This trial will only collect the occurrence of serious adverse events  as defined below and in 
Section 7.2.   An SAE is defined as an event which: 
• is fatal or life-threatening  
• results in persistent or significant disability/incapacity 
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospitaliza tion or prolongation of exis ting hospitalization, unless 
hospitalization is for: 
• routine treatment or monitoring of the st udied indication, not associated with any 
deterioration in condition 
• elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsen ed since the start of study drug 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospital admission  
• social reasons and respite care in the absence of any deterioration in the patient’s general condition 
• is medically significant, i.e. defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes listed above 
Unlike routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements; see Section 7.2 .  
7.2 Serious adverse event reporting 
To ensure patient safety, every SAE, regardless of suspected causality, occurring until 30 days after the patient has completed study CSPP100A2365E1 (defined as time of last dose of study 
drug taken or last visit whiche ver is later) must be reported to Novartis within 24 hours of 
learning of its occurrence. 
Any SAEs experienced af ter this 30 day period should only be reported to Novartis if the 
investigator suspects a causal relationship to the study drug.  
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 19 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
Within this 30 day period, recurrent episodes, complications, or progression of the initial SAE 
must be reported as follow-up to the original episode, regardless of when the event occurred. This report must be submitted within 24 hours of the investigator receiving the follow-up 
information.  An SAE that is considered comp letely unrelated to a previously reported one 
should be reported separately as a new event. 
SAE information is collected and recorded on the Serious Adverse Event Report Form.  The 
investigator must assess the relationship of an y SAE to study drug, complete the SAE Report 
Form in English, and send the completed, signed form by fax within 24 hours to the local 
Novartis Drug Safety and Epidemiology Depa rtment.  The telephone a nd telecopy number of 
the contact persons in the local department of Clinical Safety and Epidemiology, specific to the site, are listed in the investigator folder provided to each site.  The original copy of the SAE Report Form and the fax c onfirmation sheet must be kept with the case report form 
documentation at the study site. 
Follow-up information is sent to the same person to whom the original SAE Report Form was 
sent, using a new SAE Report Form stating that this is a follow-up to the previously reported SAE and giving the date of the original repor t.  The follow-up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the pa tient continued or withdrew from study participation.  
If the SAE is not previously documented in th e Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the Novartis study drug, a Drug Safety and Epidemiology Department associate may urgently require further information from the investigator for Health Authority reporting.  Novartis may need to issue an Investigator Notification (IN) to inform all investigators involved in any study with the same drug that this SAE has been reported.  Suspected Unexpected Serious Adverse Reactions (SUSARs) will be 
collected and reported to the competent authorities and relevant ethics committees in accordance with Directive 2001/20/EC or as per national regulatory requirements in 
participating countries. 
7.3 Pregnancies 
Not applicable. 
8 Data review and database management 
8.1 Site monitoring 
A Novartis representative will review this protocol and eCRFs with the investigators and their 
staff.  During the study, the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy of entries on the eCRFs, the adherence to the protocol and to Good Clinical Practice.  Key study personnel must be available to assist the field monitor during these visits. 
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospital or  clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiogra ms, and the results of any other tests or 
assessments.  All information on eCRFs must be traceable to these source documents in the 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 20 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
patient's file.  The investigator must also keep the original informed consent form signed by 
the patient (a signed copy is given to the patient). 
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency with the eCRF entries. Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, and the recording of data that will be used for all primary and safety variables.  
Additional checks of the consistency of the source data with the eCRFs are performed 
according to the study-specific m onitoring plan.  No information in source documents about 
the identity of the patients will be disclosed. 
8.2 Data collection 
Designated investigator staff will enter the data required by the protocol into the Electronic Case Report Forms using fully validated so ftware that conforms to 21 CFR Part 11 
requirements. Designated investigator site staff will not be given access to the EDC system until they have been trained.  Automatic validation programs check for data discrepancies and, by generating appropriate error messages, allow the data to be confirmed or corrected before transfer of the data to the CRO working on behalf of Novartis.  The Investigator must certify that the data entered into the Electronic Case Report Forms are complete and accurate. After database lock, the investigator will recei ve a CD-ROM or paper copies of the patient 
data for archiving at the investigational site. 
8.3 Database management and quality control 
CRO staff working on behalf of Novartis review the data entered into the eCRFs by investigational staff for completeness and accuracy  and instruct the site personnel to make any 
required corrections or additions .  Queries are sent to the investigational site using an 
electronic data query. Designated investigator site staff is required to respond to the query and confirm or correct the data.  If the electronic query system is not used, a paper Data Query Form will be faxed to the site.  Site personnel will co mplete and sign the faxed copy and fax it 
back to Novartis staff to make the correction to the database.  The signed copy of the Data Query Form is kept at the investigator site. 
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employs the Anatomical Therapeutic Chemical classification system. 
Medical history/current medical conditions and adverse events will be coded using the Medical dictionary for regulatory activities (MedDRA) terminology. 
Laboratory samples will be processed centrally and the results will be sent electronically to 
the Novartis designated CRO. 
9 Data analysis 
Unless otherwise stated, baseline refers to  the core study (CSPP100A2365) baseline and 
treatment regimen to what wa s taken in CSPP100A2365E1 study. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 21 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
9.1 Analysis sets 
The enrolled to follow-up set (EFS) will consist of all patients who sign the informed consent 
form for CSPP100A2365E2 study. 
9.2 Patient demographics and other baseline characteristics 
Patient demographics and relevant baseline characteristics will be obtained from the core 
study (CSPP100A2365) and summarized for EFS by treatment regimen in CSPP100A2365E1.  Continuous variables will be summarized with descriptive statistics (n, 
mean, standard deviation, median minimum and maximum) and categorical variables will be summarized with frequency by treat ment regimen in CSPP100A2365E1. 
9.3 Treatments  
Concomitant medication and significant non-drug therapies will be summarized with frequency for EFS by treatment regimen in CSPP100A2365E1. 
9.4 Analysis of the primary variable(s) 
9.4.1 Variable 
The primary assessment is the reporting of changes in weight, height and neurocognitive 
assessments for enrolled to follow-up set (EFS). 
9.4.2 Statistical model, hypothesis, and method of analysis 
Descriptive statistics (n, mean, standard de viation, median, minimum and maximum) of 
baseline, post-baseline values and changes from baseline will be summarized by treatment 
regimen in CSPP100A2365E1 and visit for EFS. 
For the superiority assessment of change in wei ght, the null hypothesis to be tested is that the 
mean change of weight in the aliskiren regimen is equal to that in the enalapril regimen, 
versus the alternative hypothe sis that they are not equal: 
H0: µ1 = µ 2 versus H 1: µ1 ≠ µ2 
The statistical test for change from baseline in weight will be performed using an analysis of 
covariance (ANCOVA) model with treatment regimen,  region (US, Euro), age strata (6 to 11 
years, 12 to 17 years), and hypertension etiol ogy (primary, secondary) as factors, and with 
baseline weight as covariate.  The statistical test will be made at two-sided significance level 
of 0.05. The 95% confidence interval for the pairwise comparison will be provided.    
Changes from baseline in height and derived BMI will be analyzed using the similar model. 
9.4.3 Handling of missing values/censoring/discontinuations 
Not planned. 
9.4.4 Supportive analyses 
Not planned. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 22 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
9.5 Analysis of secondary variables 
9.5.1 Key secondary variables 
Not applicable. 
9.5.2 Efficacy variables 
Not applicable. 
9.5.3 Safety variables 
The assessment of safety will be based primarily on the frequency of SAEs occurring within 
the first 30 days after the patient has comp leted study CSPP100A2365E1 (defined as time of 
last dose of study drug taken or last visit whichever is later).  SAEs experienced after this 30 day period are to be reported to Novartis if th e investigator suspects a causal relationship to 
the study drug. 
Occurrence and frequency of SAEs collected within this timeframe will be summarized by 
treatment regimen in CSPP100A2365E1, primary or gan class and preferred term, and will be 
narrated if any. 
Summary statistics by treatment regimen in CSPP100A2365E1 and visit for laboratory values 
(in patients with secondary hypertension only) will be provided.  Occurrence of significant 
abnormalities in laboratory values  from baseline will be summarize d by treatment regimen in 
CSPP100A2365E1. 
9.5.4 Pharmacokinetics 
Not applicable. 
9.5.5 Pharmacogenetics/pharmacogenomics 
Not applicable. 
9.5.6 Biomarkers 
Not applicable. 
9.5.7 PK/PD 
Not applicable. 
9.6 Sample size calculation 
All patients who successfully complete C SPP100A2365 and 2365E1 studies will be offered 
enrollment into the study CSPP100A2365E2 for 52 or 104 weeks follow-up. 
9.7 Power for analysis of key secondary variables 
Not applicable. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 23 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
9.8 Interim analyses 
Not applicable. 
10 Ethical considerations 
10.1 Regulatory and ethical compliance 
This clinical study was designed and shall be implemented and reported in accordance with 
the ICH Harmonized Tripartite Guidelines for G ood Clinical Practice, with applicable local 
regulations (including European Directive 2001/ 20/EC, US Code of Fede ral Regulations Title 
21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid 
down in the Declaration of Helsinki. 
10.2 Informed consent procedures 
Eligible patients may only be included in the study after providing written (witnessed, where required by law or regulation), IRB/IEC-approved informed consent, or, if incapable of doing so, after such consent has been provided by a legally acceptable representative of the patient. In cases where the patient’s representative gives consent, the patient should be informed about 
the study to the extent possible given his/her understanding. If the patient is capable of doing so, he/she should indicate assent by person ally signing and dating the written informed 
consent document or a separate  assent form. Informed cons ent must be obtained before 
conducting any study-specific procedures (i.e. all of  the procedures described in the protocol). 
The process of obtaining informed consent should be documented in the patient source 
documents.  
Novartis will provide to  investigators in a separate doc ument a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory requirements and is 
considered appropriate for this study. Any chan ges to the proposed consent form suggested by 
the investigator must be agreed to by Novartis  before submission to the IRB/IEC, and a copy 
of the approved version must be provided to the Novartis monitor after IRB/IEC approval. 
10.3 Responsibilities of the investigator and IRB/IEC 
The protocol and the proposed informed consen t form must be reviewed and approved by a 
properly constituted Institutional Review Board/Independent Ethics Committee/Research Ethics Board (IRB/IEC) before study start. A signed and dated statement that the protocol and informed consent have been approved by the IRB/ IEC must be given to Novartis before study 
initiation. Prior to study start, the investigator is required to sign a protocol signature page confirming his/her agreement to conduct the study in accordance with these documents and all 
of the instructions and procedures found in this protocol and to give access to all relevant data 
and records to Novartis monitors, auditors, Novartis Clinical Quality Assurance 
representatives, designated agents of Novartis, IRBs/IECs/REBs, and regulatory authorities as 
required. If an inspection of the clinical site is requested by a regulatory authority, the investigator must inform Novartis immedi ately that this request has been made. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 24 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
10.4 Publication of study protocol and results 
Novartis assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In add ition, upon study completion and 
finalization of the study report th e results of this trial will be  either submitted for publication 
and/or posted in a publicly accessible database of clinical trial results. 
11 Protocol adherence 
Investigators ascertain they will apply due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Nova rtis or its agents, if any, monitoring the 
trial to request approval of a protocol deviation, as no authorized deviations are permitted. If the investigator feels a protoc ol deviation would improve the conduct of the study this must 
be considered a protocol amendment, and unl ess such an amendment is agreed upon by 
Novartis and approved by the IRB/IEC it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR. 
11.1 Protocol Amendments 
Any change or addition to the protocol can only be made in a written protocol amendment that must be approved by Novartis, Health Authorities where required, and the IRB/IEC. Only amendments that are required for patient sa fety may be implemented prior to IRB/IEC 
approval. Notwithstanding the need for approval of formal prot ocol amendments, the 
investigator is expected to take any immediat e action required for the safety of any patient 
included in this study, even if this action re presents a deviation from the protocol. In such 
cases, Novartis should be notified of this acti on and the IRB/IEC at the study site should be 
informed within 10 working days. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 25 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
12 References 
Available upon request. 
Bornkamp B, Pinheiro J, Bretz F. (2009) MCPMod - An R Package for the design and 
analysis of dose-finding studies.  Journa l of Statistical Software; 29 (7): 1-23. 
Frampton JE, Curran MP. (2007) Aliskiren:  A review of its use in the management of 
hypertension.  Drugs; 67 (12): 1767-1792. 
Jensen C, Herold P, Brunner HR. (2008) Aliski ren:  The first renin inhibitor for clinical 
treatment.  Nature Reviews; 7: 399-410. 
McMurray JV, Pitt B, Latini R, et al. (2008) Eff ects of the oral renin inhibitor aliskiren in 
patients with symptomatic heart failure.  Circ Heart Fail; 1: 17 – 24. 
Muldoon MF, Waldstein SR, Ryan CM, et al. (2002) Effects of six anti-hypertensive 
medications on cognitive performance.  J Hypertens; 20(8):1643-52. Murray MD, Lane KA, Gao S, et al. (2002)  Preservation of cognitive function with 
antihypertensive medications: a longitudinal an alysis of a community-based sample of 
African Americans.  Arc Inter Med; 162(18): 2090-6. NHLBI (2004) The Fourth Report on the Diagnosis , Evaluation, and Treatment of High Blood 
Pressure in Children and Adolescents:  Na tional High Blood Pressure Program Working 
Group on High Blood Pressure in Children and Adolescents.  Pediatrics; 114: 555 – 576. 
Parving H, Persson F, Lewis JB, et al. (2008) Aliskiren combined with losartan in Type 2 
diabetes and nephropathy.  N Engl J Med; 358: 2433 – 46. Sorof JM, Lai D, Turner J, et al. (2004) Overweight, ethnicity, and the prevalence of 
hypertension in school-aged children.  Pediatrics; 113: 475-482. Starr JM, Whalley LJ, Deary IJ. (1996) The effects of antihypertensive treatment on cognitive 
function:  results from the HOPE study.  J Am Ger Soc; 44(4): 411-5. 
Tapaninen T, Backman JT, Kurkinen KJ, et al. (2010) Itraconazole, a P-Glycoprotein and 
CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin 
inhibiting effect of aliskiren. J Clin Ph armacol; published online 16 April 2010, DOI: 
10.1177/0091270010365885. 
Weinberger M. (2008) Are children doomed by wh at they eat and drink?  Hypertension; 51: 
615-616. Williams B, Poulter NR, Brown MJ, et al . (2004) Guidelines for management of 
hypertension:  report of the forth working party of the British Hypertension Society, 2004 
BHS IV.  J Hum Hypertens; 18(3): 139 – 185. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 26 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
13 Appendix 1: Clinically notable laboratory values 
Table 13-1 Clinically notable laboratory values 
Parameter CU 
Alert Value CU 
Units SI Alert Value SI Units 
Chemistry     
BUN >50% increase mg/dL >50% increase mmol/L 
Creatinine >50% increase mg/dL >50% increase umol/L 
Sodium >5% increase mEq/L >5% increase mmol/L 
Potassium >20% increase, >20% 
decrease, or any value 
>5.3 mEq/L >20% increase, >20% 
decrease, or any value >5.3  mmol/L 
Chloride >10% increase, >10% 
decrease mEq/L >10% increase, >10% 
decrease mmol/L 
Calcium >10% increase, >10% 
decrease mg/dL >10% increase, >10% 
decrease mmol/L 
Note:  Clinically notable laboratory values drawn after LT Visit 17 will be flagged on the laboratory 
reports sent to sites by the Central Laboratory at the same time that Novartis is notified (see Central 
Laboratory Manual for the Notable Laboratory Value Notification Process). 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT
Novartis Confidential Page 27 
Clinical Trial Protocol  Protocol No. CSPP100A2365E2 
 
14 Appendix 2:  Neurocognitive assessment 
The neurocognitive assessment of development is a sensitive marker of a cognitive change 
resulting from an insult to the brain such as head injury, toxin exposure and medication effect.   Although it was previously thought that treatment  with antihypertensive medication was a risk 
for cognitive decline in adults, there is more recent evidence that the treatment of hypertension with antihypertensive medication can improve functioning and has no effect on 
cognition or may be associated with mild decrements in performance on specific tasks of motor speed ( Muldoon, et al 2002); (Murray, et al 2002 ); (Star, et al 1996).  Neurocognitive 
growth and development will be monitored during the investigation of aliskiren in the treatment of pediatric hypertension. 
The following neurocognitive evaluations will be documented at LT V18 and at LT V19 in 
patients with secondary hypertension only. 
Table 14-1 Neurocognitive tests 
Function Test Applicable age for test Administration time 
Attention CMS Digits Forward 5 – 16 2 minutes 
Processing speed WJIII Visual Matching 3 + 5 minutes 
Working memory CMS Digits Backwards 
CMS Sequences 5 – 16 
5 – 16 2 minutes 7 minutes 
Motor speed Timed gait and tapping 6 + 2 minutes 
CMS = Children’s Memory Scale 
WJIII = Woodcock Johnson Tests of cognitive ability 
Summary statistics of the raw scores and a fr equency table for the number of patients with 
changes from LT V16 of raw test scores (positive, negative or no change) will be presented.  
No formal inferential analysis is planned. 
This document (090095af82ed4555 in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 6/17/2011 3:07:30 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by  at Fri, 17 Jun 2011 11:06:36 AM EDT